

Elon H C Van Dijk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5435516/publications.pdf>

Version: 2024-02-01

63
papers

1,878
citations

304743

22
h-index

289244

40
g-index

64
all docs

64
docs citations

64
times ranked

1166
citing authors

#	ARTICLE	IF	CITATIONS
1	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. <i>Progress in Retinal and Eye Research</i> , 2019, 73, 100770.	15.5	276
2	Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy. <i>Ophthalmology</i> , 2018, 125, 1547-1555.	5.2	209
3	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. <i>Progress in Retinal and Eye Research</i> , 2022, 86, 100973.	15.5	133
4	Reshaping ophthalmology training after COVID-19 pandemic. <i>Eye</i> , 2020, 34, 2089-2097.	2.1	104
5	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015, 122, 1907-1916.	5.2	69
6	Association of a Haplotype in the <i>NR3C2</i> Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2017, 135, 446.	2.5	61
7	Role of the Complement System in Chronic Central Serous Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2018, 136, 1128.	2.5	49
8	Discrepancy in current central serous chorioretinopathy classification. <i>British Journal of Ophthalmology</i> , 2019, 103, 737-742.	3.9	45
9	Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. <i>American Journal of Ophthalmology</i> , 2019, 205, 1-10.	3.3	44
10	Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. <i>American Journal of Ophthalmology</i> , 2022, 233, 101-110.	3.3	44
11	Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1061-1070.	1.8	42
12	Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	42
13	Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 419.	1.6	41
14	Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula. <i>Progress in Retinal and Eye Research</i> , 2021, 84, 100955.	15.5	37
15	Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. <i>Ophthalmology and Therapy</i> , 2020, 9, 329-342.	2.3	35
16	Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. <i>Medicine (United States)</i> , 2016, 95, e3457.	1.0	30
17	Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial. <i>American Journal of Ophthalmology</i> , 2020, 216, 80-89.	3.3	30
18	Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 2167-2176.	1.8	29

#	ARTICLE	IF	CITATIONS
19	Central serous chorioretinopathy in primary hyperaldosteronism. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2033-2042.	1.9	28
20	Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. <i>PLoS ONE</i> , 2018, 13, e0202549.	2.5	28
21	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. <i>European Journal of Ophthalmology</i> , 2016, 26, 442-448.	1.3	27
22	Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1395-1402.	1.9	25
23	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. <i>Frontiers in Endocrinology</i> , 2018, 9, 39.	3.5	22
24	Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. <i>Acta Ophthalmologica</i> , 2022, 100, 946-959.	1.1	22
25	FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2019, 39, 398-407.	1.7	21
26	The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy. , 2018, 59, 5682.		19
27	Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach. <i>Ophthalmology and Therapy</i> , 2020, 9, 191-203.	2.3	19
28	Evaluation of choroidal layer thickness in central serous chorioretinopathy. <i>Journal of Ophthalmic and Vision Research</i> , 2019, 14, 164.	1.0	19
29	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2019, 97, e572-e579.	1.1	18
30	Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1191-1197.	1.9	17
31	GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2020, 40, 1734-1741.	1.7	17
32	GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2019, 39, 2303-2310.	1.7	16
33	Exome sequencing in families with chronic central serous chorioretinopathy. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e00576.	1.2	15
34	Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. <i>Acta Ophthalmologica</i> , 2021, 99, 805-811.	1.1	15
35	Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1419-1425.	1.9	13
36	The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 351-361.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study. <i>Acta Ophthalmologica</i> , 2016, 94, 565-572.	1.1	12
38	SHORT-TERM FINDINGS ON OPTICAL COHERENCE TOMOGRAPHY AND MICROPERIMETRY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY PATIENTS TREATED WITH HALF-DOSE PHOTODYNAMIC THERAPY. <i>Retinal Cases and Brief Reports</i> , 2018, 12, 266-271.	0.6	12
39	Gender variation in central serous chorioretinopathy. <i>Eye</i> , 2018, 32, 1703-1709.	2.1	12
40	The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 512-524.	3.6	12
41	Spectrum of retinal abnormalities in renal transplant patients using chronic low-dose steroids. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 2443-2449.	1.9	11
42	Reply to Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. <i>American Journal of Ophthalmology</i> , 2020, 212, 187-188.	3.3	11
43	Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 2029-2035.	1.9	10
44	Central serous chorioretinopathy in active endogenous Cushing's syndrome. <i>Scientific Reports</i> , 2021, 11, 2748.	3.3	10
45	Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study. <i>Eye</i> , 2022, 36, 716-723.	2.1	10
46	Postoperative aqueous humour flare as a surrogate marker for proliferative vitreoretinopathy development. <i>Acta Ophthalmologica</i> , 2018, 96, 192-196.	1.1	9
47	Systemic complement activation in central serous chorioretinopathy. <i>PLoS ONE</i> , 2017, 12, e0180312.	2.5	9
48	SALIVARY ALPHA-AMYLASE LEVELS MAY CORRELATE WITH CENTRAL SEROUS CHORIORETINOPATHY ACTIVITY. <i>Retina</i> , 2021, 41, 2479-2484.	1.7	8
49	RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2021, 41, 2122-2131.	1.7	8
50	Antiretinal antibodies in central serous chorioretinopathy: prevalence and clinical implications. <i>Acta Ophthalmologica</i> , 2018, 96, 56-62.	1.1	7
51	Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 20446.	3.3	7
52	EFFICACY OF HALF-DOSE PHOTODYNAMIC THERAPY VERSUS HIGH-DENSITY SUBTHRESHOLD MICROPULSE LASER FOR TREATING PIGMENT EPITHELIAL DETACHMENTS IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2022, 42, 721-729.	1.7	7
53	Pimasertib-associated ophthalmological adverse events. <i>Acta Ophthalmologica</i> , 2018, 96, 712-718.	1.1	6
54	Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 905-910.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. <i>Acta Ophthalmologica</i> , 2022, 100, 89-95.	1.1	6
56	MYOPIC PRESENTATION OF CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2021, 41, 2472-2478.	1.7	6
57	Hair cortisol concentrations in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, 390-395.	1.1	5
58	Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy. <i>BMC Ophthalmology</i> , 2020, 20, 90.	1.4	5
59	Previous intravitreal injection as a risk factor of posterior capsule rupture in cataract surgery: a systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2022, 100, 614-623.	1.1	4
60	Spontaneous Resolution of Chronic Central Serous Chorioretinopathy: "Fuji Sign". <i>Ophthalmology Retina</i> , 2022, 6, 861-863.	2.4	4
61	Serous maculopathy with absence of retinal pigment epithelium (SMARPE). <i>Acta Ophthalmologica</i> , 2022, 100, 583-588.	1.1	3
62	Response to Letter to the Editor From Behar-Cohen et al.: The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2213-e2214.	3.6	2
63	Reply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2021, 222, 397-398.	3.3	0